Citations

Clear

4610 citation(s) found for "Lu, Brian".

Real-world biomarker testing patterns among patients with metastatic colorectal cancer (mCRC) treated with later lines of therapy (LOT) in the United States (US) community oncology setting.
Katta, Arvind, Hocum, Brian , Appukkutan, Sreevalsa, Cosgrove, David , Sruti, Ila, Shi, Junxin, Patton, Gregory , Babajanyan, Svetlana , Barzi, Afsaneh , Dai, Wei, Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | January 22, 2024 | Volume: 42 | Issue: 3_suppl | Pages: 163-163

10.1200/jco.2024.42.3_suppl.163 Get It

163 Background: Testing for BRAF and KRAS/NRAS mutations, HER2 amplifications, and MSI/MMR status is a standard of care for all patients with mCRC. There are limited real-world (RW) data regarding biomarker testing patterns among robust patients who are candidates for multiple LOT. We evaluated biomarker testing patterns among patients treated in community oncology practices who initiated regorafenib (REGO) and/or trifluridine/tipiracil (FTD/TPI), predominantly in 3rd or later lines of therapy. Methods: A retrospective analysis utilizing electronic medical record data from The US Oncology Network examined adult patients with mCRC who initiated REGO and/or FTD/TPI between 09/01/2015 and 11/30/2022 with follow-up until 05/31/2023. The proportion of patients tested for various biomarkers was assessed. Results: A total of 2684 mCRC patients initiated REGO and/or FTD/TPI (including 895 pts receiving both) in any LOT during the study period. The mean age of patients at baseline was 62.9 years, of whom 54.9% were male, 1599 (59.6%) patients were White and 436 (16.2%) were underrepresented minorities (Black or Hispanic/Latino). Patients were most commonly tested for KRAS mutations (75.2%) and least commonly for HER2 amplifications (22.6%). Age, gender, and race/ethnicity characteristics were similar between treatment subgroups, with 29.6% of minority and 23.1% of white patients not undergoing KRAS testing. Types of biomarkers tested and proportion of patients tested are reported in the table below. Conclusions: About one quarter of patients who were sufficiently robust to receive aggressive therapy did not undergo testing for KRAS, the oldest standard of care biomarker in CRC. We observed disparities by race/ethnicity. We also observed a correlation between rates of testing and treatment intensity, with patients who received both REGO and FTD/TPI having a higher rate of testing than those who received only one of the treatments. Understanding the pitfalls in biomarker testing will help pave the way for appropriate and equitable access to cancer care. [Table: see text]
Qualitative Analysis of Decision to Pursue Electrical Brain Stimulation by Patients With Drug-Resistant Epilepsy and Their Caregivers
Balzekas, Irena , Richardson, Jordan , Lorence, Isabella , Lundstrom, Brian N. , Worrell, Gregory A. , Sharp, Richard R. , Richardson, Jordan P , Lundstrom, Brian Nils , Sharp, Richard R , Worrell, Gregory A

Mayo Clinic

Neurology Clinical Practice | January 18, 2024 | Volume: 14 | Issue: 1 | Pages: No page available

10.1212/cpj.0000000000200245 | PMID 38585236 Get It

Adjuvant platinum versus capecitabine for residual, invasive, triple‐negative breast cancer: Patient‐reported outcomes in ECOG‐ACRIN EA1131
Tevaarwerk, Amyé , Garcia, Sofia F. , Arteaga, Carlos L. , Symmans, W. Fraser , Burnette, Brian L., Makower, Della , Block, Margaret , Morley, Kimberly, Jani, Chirag , Mescher, Craig , Dewani, Shabana J. , Brown‐Glaberman, Ursa, Flaum, Lisa , Sikov, William M. , Rodler, Eve T. , Tevaarwerk, Amye J , Garcia, Sofia F , Sparano, Joseph A , Wagner, Lynne , Symmans, W Fraser , Smith, Karen L. , Zhao, Fengmin , Mayer, Ingrid A. , Park, Ben Ho , Mayer, Erica L. , DeMichele, Angela , Sparano, Joseph A. , Wolff, Antonio C. , Miller, Kathy D. , Wagner, Lynne I.

Mayo Clinic

Cancer | January 18, 2024 | Volume: 130 | Issue: 10 | Pages: 1747-1757

10.1002/cncr.35187 | PMID 38236702 Get It

AbstractBackgroundPatient‐reported outcomes (PROs) are a better tool for evaluating the experiences of patients who have symptomatic, treatment‐associated adverse events (AEs) compared with clinician‐rated AEs. The authors present PROs assessing health‐related quality of life (HRQoL) and treatment‐related neurotoxicity for adjuvant capecitabine versus platinum on the Eastern Cooperative Oncology Group‐American College of Radiology Imaging Network (ECOG‐ACRIN) EA1131 trial (ClinicalTrials.gov identifier NCT02445391).MethodsParticipants completed the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy–Breast Cancer Symptom Index (NFBSI‐16) and the Functional Assessment of Cancer Therapy–Gynecologic Oncology Group neurotoxicity subscale (platinum arm only) at baseline, cycle 3 day 1 (C3D1), 6 months, and 15 months. Because of early termination, power was insufficient to test the hypothesis that HRQoL, as assessed by the NFBSI‐16 treatment side‐effect (TSE) subscale, would be better at 6 and 15 months in the capecitabine arm; all analyses were exploratory. Means were compared by using t‐tests or the Wilcoxon rank‐sum test, and proportions were compared by using the χ2 test.ResultsTwo hundred ninety‐six of 330 eligible patients provided PROs. The mean NFBSI‐16 TSE subscale score was lower for the platinum arm at baseline (p = .02; absolute difference, 0.6 points) and for the capecitabine arm at C3D1 (p = .04; absolute difference, 0.5 points), but it did not differ at other times. The mean change in TSE subscale scores differed between the arms from baseline to C3D1 (platinum arm, 0.15; capecitabine arm, −0.72; p = .03), but not from baseline to later time points. The mean decline in Functional Assessment of Cancer Therapy–Gynecologic Oncology Group neurotoxicity subscale scores exceeded the minimal meaningful change (1.38 points) from baseline to each subsequent time point (all p < .05).ConclusionsDespite the similar frequency of clinician‐rated AEs, PROs identified greater on‐treatment symptom burden with capecitabine and complemented clinician‐rated AEs by characterizing patients’ experiences during chemotherapy.
Burnout in Gastrointestinal Providers
Lacy, Brian E. , Cangemi, David J. , Burke, Carol A. , Burke, Carol A

Mayo Clinic

American Journal of Gastroenterology | January 18, 2024 | Volume: 119 | Issue: 7 | Pages: 1218-1221

10.14309/ajg.0000000000002663 | PMID 38235758 Get It

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes
Cerhan, James R. , Maurer, Matthew J. , Link, Brian K. , Feldman, Andrew L. , Habermann, Thomas M. , Jaye, David L. , Burack, Richard , McDonnell, Timothy J. , Vega, Francisco , Chapman, Jennifer R. , Leonard, John P. , Bernal‐Mizrachi, Leon , Alderuccio, Juan Pablo , Riska, Shaun M., Gysbers, Brianna, Lunde, Julianne J. , Reicks, Tanner W., Ayers, Amy , O’Leary, Colin B. , Yost, Kathleen J. , Nowakowski, Grzegorz S. , Ruan, Jia , Koff, Jean L. , Thompson, Carrie A. , Cohen, Jonathon B. , Lossos, Izidore S. , Friedberg, Jonathan W. , Martin, Peter W., Flowers, Christopher R. , Burack, W Richard , Syrbu, Sergei , Vij, Kiran R , Bernal-Mizrachi, Leon , Witzig, T.E. , Weiner, George , Wang, Yucai , Alderuccio, Juan Pablo , Slager, Susan L , Liu, Hongfang , Chihara, Dai , Koff, Jean L , Casulo, Carla , Thompson, Carrie A , Cohen, Jonathon B , Kahl, Brad S , Lossos, Izidore S , Feldman, Andrew L , Maurer, Matthew , Cerhan, James R , Vega, Francisco , Link, Brian K , Habermann, Thomas , Jaye, David L , Syrbu, Sergei , Inghirami, Giorgio , Farooq, Umar , Witzig, Thomas E. , Weiner, George J. , Wang, Yucai , Slager, Susan L. , Larson, Melissa C. , Liu, Hongfang , Chihara, Dai , Casulo, Carla , Kahl, Brad S. , Nastoupil, Loretta J. , Martin, Peter

Mayo Clinic

American Journal of Hematology | January 13, 2024 | Volume: 99 | Issue: 3 | Pages: 408-421

10.1002/ajh.27202 | PMID 38217361 Get It

AbstractTo address the current and long‐term unmet health needs of the growing population of non‐Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/). A total of 7735 newly diagnosed patients aged 18 years and older with NHL were prospectively enrolled from 7/1/2015 to 5/31/2020 at 8 academic centers in the United States. The median age at diagnosis was 62 years (range, 18–99). Participants came from 49 US states and included 538 Black/African‐Americans (AA), 822 Hispanics (regardless of race), 3386 women, 716 age <40 years, and 1513 rural residents. At study baseline, we abstracted clinical, pathology, and treatment data; banked serum/plasma (N = 5883, 76.0%) and germline DNA (N = 5465, 70.7%); constructed tissue microarrays for four major NHL subtypes (N = 1189); and collected quality of life (N = 5281, 68.3%) and epidemiologic risk factor (N = 4489, 58.0%) data. Through August 2022, there were 1492 deaths. Compared to population‐based SEER data (2015–2019), LEO participants had a similar distribution of gender, AA race, Hispanic ethnicity, and NHL subtype, while LEO was underrepresented for patients who were Asian and aged 80 years and above. Observed overall survival rates for LEO at 1 and 2 years were similar to population‐based SEER rates for indolent B‐cell (follicular and marginal zone) and T‐cell lymphomas, but were 10%–15% higher than SEER rates for aggressive B‐cell subtypes (diffuse large B‐cell and mantle cell). The LEO cohort is a robust and comprehensive national resource to address the role of clinical, tumor, host genetic, epidemiologic, and other biologic factors in NHL prognosis and survivorship.
Public Health Informatics and the Perioperative Physician: Looking to the Future
Gabriel, Rodney A. , Howell, Stephen, Tan, Jonathan M. , O’Reilly-Shah, Vikas N. , Poterack, Karl A. , Rothman, Brian , Poterack, Karl, Mudumbai, Seshadri C. , Howell, Stephen, Freundlich, Robert E. , Kendale, Samir M.

Mayo Clinic

Anesthesia & Analgesia | January 12, 2024 | Volume: 138 | Issue: 2 | Pages: 253-272

10.1213/ane.0000000000006649 | PMID 38215706 Get It

The role of informatics in public health has increased over the past few decades, and the coronavirus disease 2019 (COVID-19) pandemic has underscored the critical importance of aggregated, multicenter, high-quality, near-real-time data to inform decision-making by physicians, hospital systems, and governments. Given the impact of the pandemic on perioperative and critical care services (eg, elective procedure delays; information sharing related to interventions in critically ill patients; regional bed-management under crisis conditions), anesthesiologists must recognize and advocate for improved informatic frameworks in their local environments. Most anesthesiologists receive little formal training in public health informatics (PHI) during clinical residency or through continuing medical education. The COVID-19 pandemic demonstrated that this knowledge gap represents a missed opportunity for our specialty to participate in informatics-related, public health-oriented clinical care and policy decision-making. This article briefly outlines the background of PHI, its relevance to perioperative care, and conceives intersections with PHI that could evolve over the next quarter century.
Pathophysiology of Facial Nerve Stimulation and Its Implications for Electrical Stimulation in Cochlear Implants
Saoji, Aniket A. , DeJong, Melissa D., Bertsch, Natasha J., Graham, Madison K., Goulson, Kayla R., Pease, Megan L. Wernsman, Gruenwald, Jill M., Bross, Abigail E., Dornhoffer, James R. , Neff, Brian A., Driscoll, Colin L. W., Carlson, Matthew L. , Lane, John I. , Pesch, Joerg, Vanpoucke, Filiep J.

Mayo Clinic

Otology & Neurotology | January 11, 2024 | Volume: 45 | Issue: 2 | Pages: e84-e90

10.1097/mao.0000000000004082 | PMID 38206062 Get It

Objectives A small number of cochlear implant (CI) users experience facial nerve stimulation (FNS), which can manifest as facial twitching. In some patients, this can be resolved by adjusting the electrical stimulation parameters. However, for others, facial stimulation can significantly impair CI outcomes or even prevent its use. The exact mechanisms underlying FNS are unclear and may vary among patients. Design Transimpedance measurements were used to assess lateral and longitudinal spread of current within 15 cochlea of nucleus CI recipients with FNS (13 unilateral recipients and 1 bilateral recipient). We compared the transimpedance measurements with programming parameters from clinical visits and pre- and postoperative temporal bone computed tomography (CT) scans to identify factors that may contribute to FNS in each CI ear. Results In nine ears, transimpedance curves showed inflection, which suggests a localized current sink within the cochlea. This indicates a low-impedance pathway through which current exits the cochlea and stimulates the labyrinthine segment of the facial nerve canal. Electrodes near this current sink were disabled or underfit to minimize facial stimulation. In the other seven ears, current flow peaked toward the basal end of the cochlea, suggesting that current exits through the round window or other structures near the basal end of the cochlea, stimulating the tympanic segment of the facial nerve. Conclusions Objective transimpedance measurements can be used to elucidate the mechanisms of FNS and to develop strategies for optimizing electrical stimulation parameters and speech coding to minimize or eliminate FNS in a small subset of CI users.
Ultrasonic- and Ultrasound-assisted Improvement of Silhouette of the Torso: Bone Structure High-definition Remodeling (Part I)
Valdivieso, Carlos Oñate, Valdivieso, Daniel Oñate, Villa, Hugo Aguilar , Michels, Paulo Jr Alberton, Viera, Andres, Benavides, Jorge E., Flórez, Silvia Juliana Villabona , Ramírez, Brian , Perez Pachon, Mauricio E, Hoyos, Alfredo E. , Perez, Mauricio E.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | January 10, 2024 | Volume: 12 | Issue: 1 | Pages: e5513

10.1097/gox.0000000000005513 | PMID 38204869 Get It

Background: High-definition liposculpture allowed plastic surgeons to achieve better aesthetic results by carving the underlying muscles and contours in a new way. Several authors have improved the original technique by adding other procedures and new technologies. We designed a new improvement by incorporating bone transformation surgery to overcome the lack of silhouette at the waist and, as a result, optimize the breast-waist-hip ratios. Methods: We carried out a prospective multicenter study, with five different surgeons performing the same rib remodeling technique for waist definition. We used an ultrasonic piece for costal corticotomy and real-time ultrasound imaging to perform green-stick fractures over the last two or three floating ribs. Ours is a new technique based on the prior one described by Kudzaev. Results: We reported 131 consecutive patients who were enrolled in this study. Waistline diameter decreased an average of 8 cm after surgery ( P < 0.05). Most patients were women (n = 125, 95.4%). No major complications were reported. Most common complication was prolonged pain, with only three cases of contour asymmetry, all of which were attributable to noncompliance of constantly wearing the corset + compressive garments. Patients reported a high satisfaction rate and fast recovery (Body-QoL survey). Conclusions: Ultrasonic- and ultrasound- assisted indentation surgery of the thorax is a safe and reliable technique for waistline definition, with a high satisfaction rate, almost-invisible scars, and minimal risk for complications. Incorporation of high-definition liposculpture to rib remodeling opens up a new horizon for bone structure modification surgery (S-high-definition remodeling) that can be safely performed for patients who seek better aesthetic outcomes in body contouring.
Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature
Abdelbaky, Salma , Giacopelli, Brian , Rabe, Kari G. , Yamaguchi, Kyoko , Wu, Yue-Zhong, Yan, Huihuang , Shanafelt, Tait D. , Parikh, Sameer A. , Hampel, Paul J. , Brown, Sochilt , Vachon, Celine M. , Hanson, Curtis A. , Parker, Alexander S. , Oakes, Christopher C. , Ding, Wei , Hampel, Paul J , Cerhan, James R , Vachon, Celine M. , Kay, Neil E , Braggio, Esteban , Slager, Susan L , Oakes, Christopher C , Chaffee, Kari G. , Ding, Wei , Parikh, Sameer A , Shanafelt, Tait D , Ding, Wei , Cerhan, James R. , Kay, Neil E. , Braggio, Esteban , Slager, Susan L.

Mayo Clinic

Blood | January 9, 2024 | Volume: 143 | Issue: 17 | Pages: 1752-1757

10.1182/blood.2023022180 | PMID 38194687 Get It

Abstract Monoclonal B-cell lymphocytosis (MBL) progresses to chronic lymphocytic leukemia (CLL) requiring therapy at 1% to 5% per year. Improved prediction of progression would greatly benefit individuals with MBL. Patients with CLL separate into 3 distinct epigenetic subtypes (epitypes) with high prognostic significance, and recently the intermediate epitype has been shown to be enriched for high-risk immunoglobulin lambda variable (IGLV) 3-21 rearrangements, impacting outcomes for these patients. Here, we employed this combined strategy to generate the epigenetic and light chain immunoglobulin (ELCLV3-21) signature to classify 219 individuals with MBL. The ELCLV3-21 high-risk signature distinguished MBL individuals with a high probability of progression (39.9% and 71.1% at 5 and 10 years, respectively). ELCLV3-21 improved the accuracy of predicting time to therapy for individuals with MBL compared with other established prognostic indicators, including the CLL international prognostic index (c-statistic, 0.767 vs 0.668, respectively). Comparing ELCLV3-21 risk groups in MBL vs a cohort of 226 patients with CLL revealed ELCLV3-21 high-risk individuals with MBL had significantly shorter time to therapy (P = .003) and reduced overall survival (P = .03) compared with ELCLV3-21 low-risk individuals with CLL. These results highlight the power of the ELCLV3-21 approach to identify individuals with a higher likelihood of adverse clinical outcome and may provide a more accurate approach to classify individuals with small B-cell clones.
Genomic Classification and Individualized Prognosis in Multiple Myeloma
Maura, Francesco , Rajanna, Arjun Raj , Ziccheddu, Bachisio , Poos, Alexandra M. , Derkach, Andriy , Maclachlan, Kylee , Durante, Michael , Diamond, Benjamin , Papadimitriou, Marios , Davies, Faith E. , Boyle, Eileen M. , Walker, Brian A. , Hultcrantz, Malin , Silva, Ariosto, Hampton, Oliver , Teer, Jamie K. , Siegel, Erin M. , Bolli, Niccolò , Jackson, Graham , Kaiser, Martin , Cook, Gordon , Kazandjian, Dickran , Stein, Caleb, Chesi, Marta , Bergsagel, Leif, Elias, K. , Goldschmidt, Hartmut , Fenk, Roland , Rhee, Fritz Van, Usmani, Saad Z. , Shain, Kenneth H. , Weinhold, Niels , Bergsagel, P. Leif , Bergsagel, P. Leif , Davies, Faith E , Walker, Brian A , Jackson, Graham H , Pawlyn, Charlotte , Cook, Gordon , Kazandjian, Dickran , Chesi, Marta , Mai, Elias K , Goldschmidt, Hartmut , Weisel, Katja C , Fenk, Roland , Raab, Marc S , van Rhee, Frits , Usmani, Saad , Shain, Kenneth H , Weinhold, Niels , Landgren, C Ola , Bolli, Niccolo' , Boyle, Eileen M , Kaiser, Martin F , Maura, Francesco , Durante, Michael , Maclachlan, Kylee , Derkach, Andriy , Diamond, Benjamin T , Pawlyn, Charlotte , Stein, Caleb, Raab, Marc S. , Morgan, Gareth J. , Landgren, Ola

Mayo Clinic

Journal of Clinical Oncology | January 9, 2024 | Volume: 42 | Issue: 11 | Pages: 1229-1240

10.1200/jco.23.01277 | PMID 38194610 Get It

PURPOSE Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS To decipher and predict the molecular and clinical heterogeneity of NDMM, we assembled a series of 1,933 patients with available clinical, genomic, and therapeutic data. RESULTS Leveraging a comprehensive catalog of genomic drivers, we identified 12 groups, expanding on previous gene expression–based molecular classifications. To build a model predicting individualized risk in NDMM (IRMMa), we integrated clinical, genomic, and treatment variables. To correct for time-dependent variables, including high-dose melphalan followed by autologous stem-cell transplantation (HDM-ASCT), and maintenance therapy, a multi-state model was designed. The IRMMa model accuracy was significantly higher than all comparator prognostic models, with a c-index for OS of 0.726, compared with International Staging System (ISS; 0.61), revised-ISS (0.572), and R2-ISS (0.625). Integral to model accuracy was 20 genomic features, including 1q21 gain/amp, del 1p, TP53 loss, NSD2 translocations, APOBEC mutational signatures, and copy-number signatures (reflecting the complex structural variant chromothripsis). IRMMa accuracy and superiority compared with other prognostic models were validated on 256 patients enrolled in the GMMG-HD6 (ClinicalTrials.gov identifier: NCT02495922 ) clinical trial. Individualized patient risks were significantly affected across the 12 genomic groups by different treatment strategies (ie, treatment variance), which was used to identify patients for whom HDM-ASCT is particularly effective versus patients for whom the impact is limited. CONCLUSION Integrating clinical, demographic, genomic, and therapeutic data, to our knowledge, we have developed the first individualized risk-prediction model enabling personally tailored therapeutic decisions for patients with NDMM.